SCHEMBL4806320

SCHEMBL4806320

CC(C)(C)NCCCC(=O)O

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.46
SLC22A6 Q4U2R8 2/20 0.46
TSHR P16473 6/20 0.43
NFKB1 P19838 1/20 0.43
PMP22 Q01453 1/20 0.43
ADRA1A P35348 1/20 0.43
AKR1B1 P15121 1/20 0.42
PRMT1 Q99873 1/20 0.41
POLB P06746 1/20 0.41
PPARG P37231 6/20 0.41
PPARD Q03181 6/20 0.41
PPARA Q07869 6/20 0.41
GPR84 Q9NQS5 5/20 0.41
HDAC11 Q96DB2 5/20 0.41
ALDH1A1 P00352 2/20 0.41
TLR2 O60603 2/20 0.41
TDP1 Q9NUW8 2/20 0.41
FABP4 P15090 2/20 0.41
PTPN1 P18031 2/20 0.41
SLC22A8 Q8TCC7 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16491136 0.91 ADRA1A (0.55) LMNASLC22A6TSHRNFKB1PMP22
SCHEMBL13610844 0.91 ADRA1A (0.55) LMNASLC22A6TSHRNFKB1PMP22
SCHEMBL1983625 0.85 LMNA (0.40) LMNASLC22A6TSHRADRA1APOLB
Hydrochloric Acid SCHEMBL2653260 0.83 NAALAD2 (0.39) LMNASLC22A6TSHRADRA1APOLB
SCHEMBL16491130 0.82 EPHX2 (0.54) LMNATSHRADRA1APRMT1HDAC11
SCHEMBL9979452 0.82 LMNA (0.42) LMNASLC22A6TSHRNFKB1PMP22
SCHEMBL25734619 0.81 ALDH1A1 (0.41) LMNAPOLBALDH1A1MEN1KMT2A
SCHEMBL3314749 0.81 POLB (0.38) LMNAPOLBALDH1A1MEN1KMT2A
SCHEMBL8809802 0.81 POLB (0.38) LMNAPOLBALDH1A1MEN1KMT2A
SCHEMBL852157 0.80 TSHR (0.43) LMNASLC22A6TSHRNFKB1PMP22

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12594700-B2 Coatings from polyisocyanurate coatings (rim) and their use in injection molding processes COVESTRO DEUTSCHLAND AG (DE) 2026-04-07 US disclosed
EP-3601405-B1 GENERATION OF POLYISOCYANURATE LAYERS THROUGH SEPARATE APPLICATION OF ISOCYANATE COMPONENTS AND CATALYSTS COVESTRO DEUTSCHLAND AG (DE) 2024-08-28 EP disclosed
US-12043637-B2 Fluorescent dyes containing bis-boron fused heterocycles and uses in sequencing ILLUMINA CAMBRIDGE LIMITED (GB) 2024-07-23 US disclosed
US-20240067640-A1 PHENYL MALEIMIDE LINKER AGENTS FIREFLY BIO, INC. 2024-02-29 US disclosed
US-20230226207-A1 Camptothecin Drug Having High-Stability Hydrophilic Connecting Unit And Conjugate Thereof SYSTIMMUNE, INC. 2023-07-20 US disclosed
US-20230211530-A1 COATINGS FROM POLYISOCYANURATE COATINGS (RIM) AND THEIR USE IN INJECTION MOLDING PROCESSES COVESTRO DEUTSCHLAND AG (DE) 2023-07-06 US disclosed
EP-4175820-A1 COATINGS FROM POLYISOCYANURATE COATINGS (RIM) AND THEIR USE IN INJECTION MOLDING PROCESSES Covestro Deutschland AG (DE) 2023-05-10 EP disclosed
US-11638762-B2 Targeted delivery of nicotinamide adenine dinucleotide salvage pathway inhibitors SEAGEN INC. (US) 2023-05-02 US disclosed
US-20220162156-A1 COMPOSITIONS AND METHODS FOR THE TREATMENT OF IRRITABLE BOWEL SYNDROME Cellix Bio Provate Limited (IN) 2022-05-26 US disclosed
WO-2022002787-A1 COATINGS FROM POLYISOCYANURATE COATINGS (RIM) AND THEIR USE IN INJECTION MOLDING PROCESSES COVESTRO DEUTSCHLAND AG (DE) 2022-01-06 WO disclosed
US-8791142-B2 Oxazole pyridine derivatives useful as S1P1 receptor agonists MERCK SERONO S.A. (CH) 2014-07-29 US disclosed
US-8193214-B2 Chymase inhibitors BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2012-06-05 US disclosed
US-20110306636-A1 OXAZOLE PYRIDINE DERIVATIVES USEFUL AS S1P1 RECEPTOR AGONISTS MERCK SERONO SA (CH) 2011-12-15 US disclosed
US-20110306636-A1 OXAZOLE PYRIDINE DERIVATIVES USEFUL AS S1P1 RECEPTOR AGONISTS MERCK SERONO SA (CH) 2011-12-15 US disclosed
US-20100029637-A1 Chymase Inhibitors BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2010-02-04 US disclosed
US-7371807-B2 Blocked biuretized isocyanates BAYER MATERIALSCIENCE LLC (US) 2008-05-13 US disclosed
EP-1650245-B1 Biuretized polyisocyanates blocked with aralkylamines BAYER MATERIALSCIENCE LLC (US) 2007-12-19 EP disclosed
US-20060089479-A1 Blocked biuretized isocyanates COVESTRO LLC 2006-04-27 US disclosed
EP-1650245-A1 Biuretized polyisocyanates blocked with aralkylamines Bayer MaterialScience LLC (US) 2006-04-26 EP disclosed
EP-0765314-A1 BENZOHETEROCYCLIC DERIVATIVES USEFUL AS VASOPRESSIN OR OXYTOCIN MODULATORS OTSUKA PHARMACEUTICAL CO., LTD. (JP) 1997-04-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100029637-A1 Chymase Inhibitors CMA1, CPA3, SERPINB1 LMNA 1979/4885SLC22A6 2609/4885TSHR 3397/4885
US-12043637-B2 Fluorescent dyes containing bis-boron fused heterocycles and uses in sequencing BLVRB, BCDIN3D, FOSB LMNA 386/4885SLC22A6 623/4885TSHR 3478/4885
US-20220162156-A1 COMPOSITIONS AND METHODS FOR THE TREATMENT OF IRRITABLE BOWEL SYNDROME SI, SLC10A2, F5 LMNA 4229/4885SLC22A6 339/4885TSHR 3380/4885
US-20230226207-A1 Camptothecin Drug Having High-Stability Hydrophilic Connecting Unit And Conjugate Thereof SLC7A1, CD44, DCLRE1A LMNA 2482/4885SLC22A6 54/4885TSHR 1385/4885
US-12594700-B2 Coatings from polyisocyanurate coatings (rim) and their use in injection molding processes TST, C9, ESD LMNA 4756/4885SLC22A6 2684/4885TSHR 3835/4885
US-20110306636-A1 OXAZOLE PYRIDINE DERIVATIVES USEFUL AS S1P1 RECEPTOR AGONISTS S1PR1, S1PR3, S1PR5 LMNA 3976/4885SLC22A6 3180/4885TSHR 783/4885
US-20240067640-A1 PHENYL MALEIMIDE LINKER AGENTS TPX2, H1-4, MAPT LMNA 233/4885SLC22A6 344/4885TSHR 1144/4885
US-11638762-B2 Targeted delivery of nicotinamide adenine dinucleotide salvage pathway inhibitors NAMPT, NME4, NNMT LMNA 1619/4885SLC22A6 682/4885TSHR 1404/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.